Radiotherapy for Oropharyngeal Carcinoma With an Uninvolved Contralateral Neck: The Safety of Omission of Contralateral High Level II and Retropharyngeal Lymph Nodes From Elective Target Volumes

• Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) 2021-05, Vol.33 (5), p.331-339
• Main Authors: Iyizoba-Ebozue, Z., Murray, L.J., Ramasamy, S., Sen, M., Murray, P., Cardale, K., Dyker, K., Prestwich, R.J.D.
• Format: Article
• Language: English
• Subjects: Level 2 lymph nodes; oropharyngeal cancer; radiotherapy; retropharyngeal lymph nodes
• ISSN: 0936-6555; 1433-2981
• DOI: 10.1016/j.clon.2020.12.007

To analyse outcomes and patterns of failure in patients with oropharyngeal carcinoma (OPC) treated with definitive volumetric modulated arc therapy with omission of contralateral high level II lymph nodes (HLII) and retropharyngeal lymph nodes (RPLN) in the contralateral uninvolved neck. Patients with OPC treated between January 2016 and July 2019 were retrospectively identified. In the absence of contralateral neck disease, institutional protocols allowed omission of contralateral HLII and contralateral RPLN in the additional absence of ipsilateral RPLN, soft palate/posterior pharyngeal wall primary. In total, 238 patients with OPC and an uninvolved contralateral neck received definitive (chemo)radiotherapy with bilateral neck treatment. The median follow-up was 30.6 months. Two-year local control, regional control and overall survival were 91.0, 91.6 and 86.5%, respectively. Contralateral HLII were omitted in 159/238 (66.8%) patients; this included 106 patients in whom the primary tumour was at/crossed the midline. The contralateral RPLN region was omitted from elective target volumes for 175/238 (73.5%); this included 114 patients with a primary tumour at/crossed the midline. The mean contralateral parotid dose when contralateral HLII and RPLN were both omitted was 24.4 Gy, compared with 28.3 Gy without HLII/RPLN omission (P < 0.001). Regional progression occurred in 18/238 (7.6%) patients, all involving the ipsilateral neck with one bilateral. There were no recurrences in the contralateral HLII or RPLN regions. In patients with OPC and an uninvolved contralateral neck receiving bilateral (chemo)radiotherapy, the omission of contralateral RPLN and HLII from elective target volumes was safe and could lead to reduced contralateral parotid doses. •Radiotherapy for oropharynx cancer requires elective treatment of at-risk lymph nodes.•Limiting target volumes may reduce toxicity.•Omission of contralateral high level II and retropharyngeal lymph nodes was safe.•Omission could lead to lower contralateral parotid doses.